Ketamine-enhanced Prolonged Exposure Therapy in PTSD
Primary Purpose
PTSD
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ketamine
Midazolam
Sponsored by

About this trial
This is an interventional treatment trial for PTSD focused on measuring Post-traumatic Stress Disorder
Eligibility Criteria
Inclusion Criteria:
- male or female Veterans between the ages of 18 and 75 years
- diagnosis of PTSD
- ability to provide written informed consent
Exclusion Criteria:
- females who are currently pregnant or breastfeeding
- current high risk for suicide
- history of moderate/severe head injury
- history of psychosis
- current episode of mania/hypomania
- severe substance and/or alcohol use disorder in the last 6 months
Sites / Locations
- Minneapolis VA Health Care System, Minneapolis, MNRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Ketamine and prolonged exposure (PE)
Midazolam and prolonged exposure (PE)
Arm Description
Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Outcomes
Primary Outcome Measures
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
The CAPS-5 is the gold standard in PTSD assessment consisting of a a 30-item structured interview. The CAPS-5 will be recorded and aggregated from all study participants. Range from 0 to 80 with higher score denoting more severe PTSD symptoms.
Secondary Outcome Measures
Full Information
NCT ID
NCT04560660
First Posted
September 17, 2020
Last Updated
May 15, 2023
Sponsor
VA Office of Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT04560660
Brief Title
Ketamine-enhanced Prolonged Exposure Therapy in PTSD
Official Title
Repeated Ketamine Treatment to Accelerate Efficacy of Prolonged Exposure in PTSD
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 9, 2021 (Actual)
Primary Completion Date
June 18, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.
Detailed Description
In this single site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine in conjunction with prolonged exposure (PE) therapy for PTSD. Veterans who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of two treatment arms (placebo plus PE vs ketamine plus PE). Participants receive the study drug via intravenous infusion once per week for 3-weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PTSD
Keywords
Post-traumatic Stress Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Subjects will be randomly assigned to one of two parallel treatment conditions: 1) adjunctive ketamine infusions to prolonged exposure therapy or 2) adjunctive midazolam (active placebo) infusions to prolonged exposure therapy.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The investigators will use a sequentially numbered, opaque, sealed envelopes, pharmacy-controlled allocations, and coded identical containers for adequate concealment allocation. Administration of study drugs and infusion monitoring will be conducted by research nurse keeping blinding from investigators and independent outcome assessors.
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ketamine and prolonged exposure (PE)
Arm Type
Experimental
Arm Description
Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Arm Title
Midazolam and prolonged exposure (PE)
Arm Type
Placebo Comparator
Arm Description
Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
FDA approved anesthetic medication with rapid acting antidepressant effects.
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
FDA approved sedative medication with dissociative effects.
Primary Outcome Measure Information:
Title
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Description
The CAPS-5 is the gold standard in PTSD assessment consisting of a a 30-item structured interview. The CAPS-5 will be recorded and aggregated from all study participants. Range from 0 to 80 with higher score denoting more severe PTSD symptoms.
Time Frame
CAPS-5 to measure change in PTSD symptoms from baseline to post-treatment (10 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
male or female Veterans between the ages of 18 and 75 years
diagnosis of PTSD
ability to provide written informed consent
Exclusion Criteria:
females who are currently pregnant or breastfeeding
current high risk for suicide
history of moderate/severe head injury
history of psychosis
current episode of mania/hypomania
severe substance and/or alcohol use disorder in the last 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paulo R Shiroma, MD
Phone
(612) 725-2000
Ext
612467
Email
Paulo.Shiroma@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paulo R Shiroma, MD
Organizational Affiliation
Minneapolis VA Health Care System, Minneapolis, MN
Official's Role
Principal Investigator
Facility Information:
Facility Name
Minneapolis VA Health Care System, Minneapolis, MN
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55417-2309
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gloria Wang, BS
Phone
612-467-2974
Email
gloria.wang2@va.gov
First Name & Middle Initial & Last Name & Degree
Paulo R Shiroma, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Ketamine-enhanced Prolonged Exposure Therapy in PTSD
We'll reach out to this number within 24 hrs